Aspirin as a chemoprevention agent for colorectal cancer

Current Drug Metabolism

Volumn 13, Issue 9, 2012, Pages 1313-1322

  Lee, Chun Seng ^a   McNamara, Deirdre ^a   O'Morain, Colm A ^a  

^a ADELAIDE AND MEATH HOSPITAL   (Ireland)

Author keywords

Aspirin; Chemoprevention; Colorectal cancer; Cyclooxygenase

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA DEFENSIN; BETA CATENIN; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; DICLOFENAC; IBUPROFEN; INDOMETACIN; INTERLEUKIN 6; NEUTROPHIL GELATINASE ASSOCIATED LIPOCALIN; PLACEBO; PROTEIN BCL 2; PROTEIN BCL XL; ROFECOXIB; SULINDAC;

ADENOMATOUS POLYP; APOPTOSIS; CELL PROLIFERATION; CHEMOPROPHYLAXIS; COLON ADENOMA; COLONOSCOPY; COLORECTAL CANCER; COST EFFECTIVENESS ANALYSIS; DOSE RESPONSE; DRUG HALF LIFE; DRUG METABOLISM; ENZYME INHIBITION; GASTROINTESTINAL HEMORRHAGE; HEALTH CARE SYSTEM; HUMAN; IMMUNE SYSTEM; KIDNEY FAILURE; LOW DRUG DOSE; LYMPH VESSEL METASTASIS; NONHUMAN; PRIMARY PREVENTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR VOLUME;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTICARCINOGENIC AGENTS; ASPIRIN; COLORECTAL NEOPLASMS; COST-BENEFIT ANALYSIS; HUMANS;

EID: 84868013085     PISSN: 13892002     EISSN: 18755453     Source Type: Journal    
DOI: 10.2174/138920012803341384     Document Type: Review

References (128)

1. Morson, B. President's address. The polyp-cancer sequence in the large bowel. Proc. R. Soc. Med., 1974, 67(6 Pt 1), 451-7.
2. Takayama, T.; Katsuki, S.; Takahashi, Y.; Ohi, M.; Nojiri, S.; Sakamaki, S.; Kato, J.; Kogawa, K.; Miyake, H.; Niitsu, Y. Aberrant crypt foci of the colon as precursors of adenoma and cancer. N. Engl. J. Med., 1998, 339(18), 1277-84.
3. Ferlay, J.; Shin, H.R; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. GLOBOCAN 2008 v1.2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [Internet].) Lyon, France: International Agency for Research on Cancer; 2010. Available from: http://globocan.iarc.fr, accessed on 17/7/2011.
4. Ferlay, J.; Parkin, D.M.; Steliarova-Foucher., E. Estimates of cancer incidence and mortality in Europe in 2008. Eur. J. Cancer, 2010, 46(4), 765-81.
5. Center, M.M.; Jemal, A.; Smith, R.A.; Ward, E. Worldwide variations in colorectal cancer. CA Cancer J. Clin., 2009, 59(6), 366-78.
6. Jemal, A.; Siegel, R; Xu., J; Ward, E. Cancer statistics, 2010. CA Cancer J. Clin., 2010, 60(5), 277-300.
7. Yabroff, K.R.; Warren, J.L.; Brown, M.L. Costs of cancer care in the USA: a descriptive review. Nat. Clin. Pract. Oncol., 2007, 4(11),643-56.
8. Lang, K.; Lines, L.M.; Lee, D.W.; Korn, J.R.; Earle, C.C; Menzin, J. Lifetime and treatment-phase costs associated with colorectal cancer: evidence from SEER-Medicare data. Clin. Gastroenterol. Hepatol., 2009, 7(2),198-204.
9. Gellad, Z.F.; Provenzale, D. Colorectal cancer: national and international perspective on the burden of disease and public health impact. Gastroenterology, 2010, 138(6), 2177-90.
10. Brenner, H.; Bouvier, A.M.; Foschi, R.; Hackl., M.; Larsen, I.K.; Lemmens, V., Mangone, L.; Francisci, S. The EUROCARE Working Group. Progress in colorectal cancer survival in Europe, from the late 1980s to the early 21st century: The EUROCARE study. Int. J. Cancer, 2011, 131, 1649-1658
11. Hewitson, P.; Glasziou, P.; Irwig, L.; Towler, B.; Watson, E. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst. Rev., 2007, (1), CD001216.
12. Winawer, S.J.; Zauber, A.G.; Ho, M.N.; O'Brien, M.J.; Gottlieb, L.S.; Sternberg, S.S.; Waye, J.D.; Schapiro, M.; Bond, J.H.; Panish, J.F; Ackroyd, F.; Shike, M.; Kurtz, R.C.; Hornsby-Lewis, L.; Gerdes, H.; Stewart, E.T. the National Polyp Study Workgroup. Prevention of colorectal cancer by colonoscopic polypectomy. N. Engl. J. Med., 1993, 329(27), 1977-81.
13. Winawer, S.J.; Zauber, A.G. Colonoscopic polypectomy and the incidence of colorectal cancer. Gut, 2001, 48(6),753-4.
14. Heitman, S.J.; Hilsden, R.J.; Au, F.; Dowden, S.; Manns, B.J. Colorectal cancer screening for average-risk North Americans: an economic evaluation. PLoS Med., 2010, 7(11), e1000370.
15. Dunn, J.E. Cancer epidemiology in populations of the United States - with emphasis on Hawaii and California - and Japan. Cancer Res., 1975, 35(11 Pt. 2), 3240-5.
16. Kune, G.A.; Kune, S.; Watson, L.F. Colorectal cancer risk, chronic illnesses, operations, and medications: case control results from the Melbourne Colorectal Cancer Study. Cancer Res., 1988, 48(15), 4399-404.
17. Thun, M.J.; Namboodiri, M.M.; Heath, C.W. Aspirin use and reduced risk of fatal colon cancer. N. Engl. J. Med., 1991, 325(23), 1593-6.
18. Rosenberg, L.; Palmer, J.R; Zauber, A.G; Warshauer, M.E.; Stolley, P.D.; Shapiro, S. A hypothesis: nonsteroidal anti-inflammatory drugs reduce the incidence of large-bowel cancer. J. Natl. Cancer Inst., 1991, 83(5), 355-8.
19. Fuster, V.; Sweeny, J.M. Aspirin: a historical and contemporary therapeutic overview. Circulation, 2011, 123(7),768-78.
20. Vane, J.R.; Botting, R.M. The mechanism of action of aspirin. Thromb. Res., 2003, 110(5-6), 255-8.
21. Rao, P.; Knaus, E.E. Evolution of nonsteroidal anti-inflammatory drugs (NSAIDs): cyclooxygenase (COX) inhibition and beyond. J. Pharm. Sci., 2008, 11(2), 81s-110s.
22. Taketo, M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (part I). J. Natl. Cancer Inst., 1998, 90(20), 1529-36.
23. Warner, T.D.; Giuliano, F.; Vojnovic, I.; Bukasa, A.; Mitchell, J.A.; Vane, J.R. Nonsteroid drug selectivities for cyclo-oxygenase-1 rather than cyclo-oxygenase-2 are associated with human gastrointestinal toxicity: a full in vitro analysis. Proc. Natl. Acad. Sci. U. S. A., 1999, 96(13), 7563-8.
24. Burton, M.E. Applied pharmacokinetics & pharmacodynamics: Principles of therapeutic drug monitoring. Lippincott Williams & Wilkins; 2006.
25. Rowland, M.; Riegelman, S.; Harris, P.A.; Sholkoff, S.D. Absorption kinetics of aspirin in man following oral administration of an aqueous solution. J. Pharm. Sci., 1972, 61(3), 379-85.
26. Higgs, G.A.; Salmon, J.A.; Henderson, B.; Vane, J.R. Pharmacokinetics of aspirin and salicylate in relation to inhibition of arachido-nate cyclooxygenase and antiinflammatory activity. Proc. Natl. Acad. Sci. U. S. A., 1987, 84(5),1417-20.
27. Boreham, D.R.; Martin, B.K. The kinetics of elimination of salicylic acid and the formation of gentisic acid. Br. J. Pharmacol., 1969, 37(1), 294-300.
28. Needs, C.J.; Brooks, P.M. Clinical pharmacokinetics of the salicy-lates. Clin. Pharmacokinet., 1985, 10(2),164-77.
29. Miners, J.O.; Grgurinovich, N.; Whitehead, A.G.; Robson, R.A.; Birkett, D.J. Influence of gender and oral contraceptive steroids on the metabolism of salicylic acid and acetylsalicylic acid. Br. J. Clin. Pharmacol., 1986, 22(2),135-42.
30. Montgomery, P.R.; Sitar, D.S. Increased serum salicylate metabolites with age in patients receiving chronic acetylsalicylic acid therapy. Gerontology, 1981, 27(6), 329-33.
31. Cummings, K.B.; Wheelis, R.F.; Robertson, R.P. Prostaglandin: increased production by renal cell carcinoma. Surg. Forum, 1975, 26, 572-4.
32. Husby, G.; Strickland, R.G.; Rigler, G.L.; Peake, G.T.; Williams, R.C. Direct immunochemical detection of prostaglandin-E and cyclic nucleotides in human malignant tumors. Cancer, 1977, 40(4), 1629-42.
33. Karmali, R.A.; Thaler, H.T.; Cohen, L.A. Prostaglandin concentrations and prostaglandin synthetase activity in N-nitrosomethylurea-induced rat mammary adenocarcinoma. Eur. J. Cancer Clin. Oncol., 1983, 19(6),817-23.
34. Rigas, B.; Goldman, I.S.; Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med., 1993, 122(5), 518-23.
35. Pugh, S; Thomas, GA. Patients with adenomatous polyps and carcinomas have increased colonic mucosal prostaglandin E2. Gut, 1994, 35(5), 675-8.
36. Bennett, A.; Houghton, J.; Leaper, D.J.; Stamford, I.F. Cancer growth, response to treatment and survival time in mice: beneficial effect of the prostaglandin synthesis inhibitor flurbiprofen. Prosta-glandins, 1979, 17(2),179-91.
37. Plescia, O.J.; Smith, A.H.; Grinwich, K. Subversion of immune system by tumor cells and role of prostaglandins. Proc. Natl. Acad. Sci. U. S. A., 1975, 72(5), 1848-51.
38. Ross, D.S.; Bitzer, D.; Roy, T.; Murphy, J.E. Piroxicam inhibits the growth of an adenocarcinoma isograft in Fischer rats. J. Surg. Res., 1988, 45(3), 249-53.
39. Reddy, B.S; Maruyama, H.; Kelloff, G. Dose-related inhibition of colon carcinogenesis by dietary piroxicam, a nonsteroidal antiinflammatory drug, during different stages of rat colon tumor development. Cancer Res., 1987, 47(20), 5340-6.
40. Waddell, W.R.; Loughry, R.W. Sulindac for polyposis of the colon. J. Surg. Oncol., 1983, 24(1),83-7.
41. Waddell, W.R.; Ganser, G.F.; Cerise, E.J.; Loughry, R.W. Sulindac for polyposis of the colon. Am. J. Surg., 1989, 157(1), 175-9.
42. Nugent, K.P.; Farmer, K.C.; Spigelman., A.D.; Williams, C.B.; Phillips, R.K. Randomized controlled trial of the effect of sulindac on duodenal and rectal polyposis and cell proliferation in patients with familial adenomatous polyposis. Br. J. Surg., 1993, 80(12),1618-9.
43. Rigau, J.; Piqué, J.M.; Rubio, E.; Planas, R.; Tarrech, J.M.; Bordas, J.M. Effects of long-term sulindac therapy on colonic polyposis. Ann. Intern. Med., 1991, 115(12), 952-4.
44. Winde, G.; Gumbinger, H.G.; Osswald, H.; Kemper, F.; Bünte, H. The NSAID sulindac reverses rectal adenomas in colectomized patients with familial adenomatous polyposis: clinical results of a dose-finding study on rectal sulindac administration. Int. J. Colorectal Dis., 1993, 8(1), 13-7.
45. Taketo, M.M. Cyclooxygenase-2 inhibitors in tumorigenesis (Part II). J. Natl. Cancer Inst., 1998, 90(21),1609-20.
46. Eberhart, C.E.; Coffey, R.J.; Radhika, A.; Giardiello, F.M.; Ferrenbach, S.; DuBois, R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology, 1994, 107(4), 1183-8.
47. Kargman, S.L.; O'Neill, G.P.; Vickers, P.J.; Evans, J.F.; Mancini, J.A.; Jothy, S. Expression of prostaglandin G/H synthase-1 and -2 protein in human colon cancer. Cancer Res., 1995, 55(12), 2556-9.
48. Benamouzig, R.; Uzzan, B.; Martin, A.; Deyra, J.; Little, J.; Girard, B; Chaussade, S. for the APACC Study Group. Cyclooxygenase-2 expression and recurrence of colorectal adenomas: effect of aspirin chemoprevention. Gut, 2010, 59(5), 622-9.
49. Sinicrope, FA.; Lemoine, M.; Xi, L.; Lynch, P.M.; Cleary, K.R.; Shen, Y.; Frazier, M.L. Reduced expression of cyclooxygenase 2 proteins in hereditary nonpolyposis colorectal cancers relative to sporadic cancers. Gastroenterology, 1999, 117(2),350-8.
50. Masunaga, R.; Kohno, H.; Dhar, D.K.; Ohno, S.; Shibakita, M.; Kinugasa, S.; Yoshimura, H.; Tachibana, M.; Kubota, H.; Nagasue, N. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin. Cancer Res., 2000, 6(10), 4064-8.
51. Sheehan, K.M.; Sheahan, K.; O'Donoghue, D.P.; MacSweeney, F.; Conroy, R.M.; Fitzgerald, D.J.; Murray, F.E. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA, 1999, 282(13),1254-7.
52. Soumaoro, L.T.; Uetake, H.; Higuchi, T.; Takagi, Y.; Enomoto, M.; Sugihara, K. Cyclooxygenase-2 expression: a significant prognostic indicator for patients with colorectal cancer. Clin Cancer Res., 2004, 10(24), 8465-71.
53. Oshima, M.; Dinchuk, J.E.; Kargman, S.L.; Oshima, H.; Hancock, B.; Kwong, E.; Trzaskos, J.M.; Evans, J.F.; Taketo, M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell, 1996, 87(5), 803-9.
54. Barry, E.L.; Sansbury, L.B.; Grau, M.V.; Ali, I.U.; Tsang, S.; Munroe, D.J.; Ahnen, D.J.; Sandler, R.S.; Saibil, F.; Gui, J.; Bresalier, R.S.; McKeown-Eyssen, G.E.; Burke, C.; Baron, JA. Cyclooxygenase-2 polymorphisms, aspirin treatment, and risk for colorectal adenoma recurrence - data from a randomized clinical trial. Cancer Epidemiol. Biomarkers Prev., 2009, 18(10), 2726-33.
55. Greenhough, A.; Smartt, H.J.; Moore, A.E.; Roberts, H.R.; Williams, A.C.; Paraskeva, C.; Kaidi, A. The COX-2/PGE2 pathway: key roles in the hallmarks of cancer and adaptation to the tumour microenvironment. Carcinogenesis, 2009, 30(3), 377-86.
56. Terzic, J.; Grivennikov, S.; Karin, E.; Karin, M. Inflammation and colon cancer. Gastroenterology, 2010, 138(6), 2101-2114.e5.
57. Chan, TA; Morin, PJ; Vogelstein, B; Kinzler, KW; Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. U. S. A., 1998, 95(2), 681-6.
58. Cao, Y.; Pearman, A.T.; Zimmerman, G.A.; McIntyre, T.M.; Prescott, S.M. Intracellular unesterified arachidonic acid signals apoptosis. Proc. Natl. Acad. Sci. U. S. A., 2000, 97(21),11280-5.
59. Jana, N.R. NSAIDs and apoptosis. Cell Mol Life Sci., 2008, 65(9), 1295-301.
60. Tian, Y.; Ye, Y.; Gao, W.; Chen, H.; Song, T.; Wang, D.; Mao, X.; Ren, C. Aspirin promotes apoptosis in a murine model of colorectal cancer by mechanisms involving downregulation of IL-6-STAT3 signaling pathway. Int. J. Colorectal. Dis., 2011, 26(1), 13-22.
61. Zhang, X.; Morham, S.G.; Langenbach, R.; Young, D.A. Malignant transformation and antineoplastic actions of nonsteroidal antiin-flammatory drugs (NSAIDs) on cyclooxygenase-null embryo fi-broblasts. J. Exp. Med., 1999, 190(4), 451-59.
62. Soh, J.W.; Weinstein, I.B. Role of COX-independent targets of NSAIDs and related compounds in cancer prevention and treatment. Prog. Exp. Tumor Res., 2003, 37261-85.
63. Bousserouel, S.; Gosse, F.; Bouhadjar, M.; Soler, L.; Marescaux, J.; Raul, F. Long-term administration of aspirin inhibits tumour formation and triggers anti-neoplastic molecular changes in a preclinical model of colon carcinogenesis. Oncol Rep. 2010, 23(2), 511-7.
64. Ho, G.Y.; Xue, X.; Cushman, M.; McKeown-Eyssen, G.; Sandler, R.S.; Ahnen, D.J.; Barry, E.L.; Saibil, F.; Bresalier, R.S.; Rohan, T.E.; Baron, J.A. Antagonistic effects of aspirin and folic acid on inflammation markers and subsequent risk of recurrent colorectal adenomas. J. Natl. Cancer Inst., 2009, 101(23), 1650-4.
65. Yin, M.J.; Yamamoto, Y.; Gaynor, R.B. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature, 1998, 396(6706),77-80.
66. Greenspan, E.J.; Madigan, J.P.; Boardman, L.A.; Rosenberg, D.W. Ibuprofen inhibits activation of nuclear {beta}-catenin in human colon adenomas and induces the phosphorylation of GSK-3{beta}. Cancer Prev. Res. (Phila)., 2011, 4(1),161-71.
67. Bergman, M.; Djaldetti, M.; Salman, H.; Bessler, H. Inflammation and colorectal cancer: does aspirin affect the interaction between cancer and immune cells? Inflammation, 2011, 34(1), 22-8.
68. Suh, O.; Mettlin, C.; Petrelli, N.J. Aspirin use, cancer, and polyps of the large bowel. Cancer, 1993, 72(4),1171-7.
69. La Vecchia, C.; Negri, E.; Franceschi, S.; Conti, E.; Montella, M.; Giacosa, A.; Falcini, A.; Decarli, A. Aspirin and colorectal cancer. Br. J. Cancer, 1997, 76(5), 675-7.
70. Friedman, G.D.; Coates, A.O.; Potter, J.D.; Slattery, M.L. Drugs and colon cancer. Pharmacoepidemiol. Drug Saf., 1998, 7(2), 99-106.
71. Hoffmeister, M.; Chang-Claude, J.; Brenner, H. Individual and joint use of statins and low-dose aspirin and risk of colorectal cancer: a population-based case-control study. Int. J. Cancer, 2007, 121(6), 1325-30.
72. Johnson, C.C.; Hayes, R.B.; Schoen, R.E.; Gunter, M.J.; Huang, W.Y. the PLCO Trial Team. Non-steroidal anti-inflammatory drug use and colorectal polyps in the Prostate, Lung, Colorectal, And Ovarian Cancer Screening Trial. Am. J. Gastroenterol., 2010, 105(12), 2646-55.
73. Din, F.V.; Theodoratou, E.; Farrington, S.M.; Tenesa, A.; Barnetson, R.A.; Cetnarskyj, R.; Stark, L.; Porteous, M.E.; Campbell, H.; Dunlop, M. Effect of aspirin and NSAIDs on risk and survival from colorectal cancer. Gut, 2010, 59(12),1670-9.
74. Huang, L.; Wang, X.; Gong, W.; Huang, Y.; Jiang, B. The comparison of the clinical manifestations and risk factors of colorectal cancer and adenomas: results from a colonoscopy-based study in southern Chinese. Int. J. Colorectal Dis., 2010, 25(11),1343-51.
75. Muscat, J.E.; Stellman, S.D.; Wynder, E.L. Nonsteroidal antiin-flammatory drugs and colorectal cancer. Cancer. 1994, 74(7),1847-54.
76. Paganini-Hill, A.; Chao, A.; Ross, R.K.; Henderson, B.E. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ, 1989, 299(6710),1247-50.
77. Thun, M.J.; Namboodiri, M.M.; Calle, E.E.; Flanders, W.D.; Heath, C.W. Aspirin use and risk of fatal cancer. Cancer Res., 1993, 53(6), 1322-7.
78. Giovannucci, E.; Rimm, E.B.; Stampfer, M.J.; Colditz, G.A.; Ascherio, A.; Willett, W.C. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann. Intern. Med., 1994, 121(4),241-6.
79. Schreinemachers, D.M.; Everson, R.B. Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology, 1994, 5(2), 138-46.
80. Giovannucci, E.; Egan, K.M.; Hunter, D.J.; Stampfer, M.J.; Colditz, G.A.; Willett, W.C.; Speizer, F.E. Aspirin and the risk of colorectal cancer in women. N. Engl. J. Med., 1995, 333(10),609-14.
81. Stürmer, T.; Glynn, R.J.; Lee, I.M.; Manson, J.E.; Buring, J.E.; Hennekens, C.H. Aspirin use and colorectal cancer: post-trial follow-up data from the Physicians' Health Study. Ann. Intern. Med., 1998, 128(9),713-20.
82. García-Rodríguez, L.A.; Huerta-Alvarez, C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin non-steroidal antiinflammatory drugs. Epidemiology, 2001, 12(1), 88-93.
83. Chan, A.T.; Giovannucci, E.L.; Meyerhardt, J.A.; Schernhammer, E.S.; Curhan, G.C.; Fuchs, C.S. Long-term use of aspirin and non-steroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA. 2005, 294(8), 914-23.
84. Allison, M.; Garland, C.; Chlebowski, R.; Criqui, M.; Langer, R.; Wu, L.; Roy., H.; McTiernan, A.; Kuller, L. the Women's Health Initiative Investigators. The association between aspirin use and the incidence of colorectal cancer in women. Am. J. Epidemiol., 2006, 164(6),567-75.
85. Larsson, S.C; Giovannucci, E.; Wolk, A. Long-term aspirin use and colorectal cancer risk: a cohort study in Sweden. Br. J. Cancer., 2006, 95(9):1277-9.
86. Chan, A.T.; Giovannucci, E.L.; Meyerhardt, J.A.; Schernhammer, E.S.; Wu, K.; Fuchs, C.S. Aspirin dose and duration of use and risk of colorectal cancer in men. Gastroenterology, 2008, 134(1), 21-8.
87. Wei, E.K.; Colditz, G.A.; Giovannucci, E.L.; Fuchs, C.S.; Rosner, B.A. Cumulative risk of colon cancer up to age 70 years by risk factor status using data from the Nurses' Health Study. Am. J. Epidemiol., 2009, 170(7), 863-72.
88. Leggett, B.; Whitehall, V. Role of the serrated pathway in colorectal cancer pathogenesis. Gastroenterology, 2010, 138(6), 2088-100.
89. Gann, P.H.; Manson, J.E.; Glynn, R.J.; Buring, J.E.; Hennekens, C.H. Low-dose aspirin and incidence of colorectal tumors in a randomized trial. J. Natl. Cancer. Inst., 1993, 85(15),1220-4.
90. Cook, N.R.; Lee, I.M.; Gaziano, J.M.; Gordon, D.; Ridker, P.M.; Manson, J.E.; Hennekens, C.H.; Buring, J.E. Low-dose aspirin in the primary prevention of cancer: the Women's Health Study: a randomized controlled trial. JAMA, 2005, 294(1), 47-55.
91. Flossmann, E.; Rothwell, P.M. British Doctors Aspirin Trial and the UK-TIA Aspirin Trial. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet, 2007, 369(9573), 1603-13.
92. Farrell, B.; Godwin, J.; Richards, S.; Warlow, C. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J. Neurol. Neurosurg. Psychiatry, 1991, 54(12),1044-54.
93. Peto, R.; Gray, R.; Collins, R.; Wheatley, K.; Hennekens, C.; Jamrozik, K.; Warlow, C.; Hafner, B.; Thompson, E.; Norton, S.; Gilliland, J.; Doll, R. Randomised trial of prophylactic daily aspirin in British male doctors. Br. Med. J. (Clin. Res. Ed), 1988, 296(6618), 313-6.
94. Rothwell, P.M.; Wilson, M.; Elwin, C.E.; Norrving, B.; Algra, A.; Warlow, C.P.; Meade, T.W. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet, 2010, 376(9754), 1741-50.
95. Baron, J.A.; Cole, B.F.; Sandler, R.S.; Haile, R.W.; Ahnen, D.; Bresalier, R.; McKeown-Eyssen, G.; Summers, R.W.; Rothstein, R.; Burke, C.A.; Snover, D.C.; Church, T.R.; Allen, J.I.; Beach, M.; Beck, G.J.; Bond, J.H.; Byers, T.; Greenberg, E.R.; Mandel, J.S.; Marcon, N.; Mott, L.A.; Pearson, L.; Saibil, F.; van Stolk, R.S. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med., 2003, 348(10), 891-9.
96. Logan, R.F.; Grainge, M.J.; Shepherd, V.C.; Armitage, N.C.; Muir, K.R ukCAP Trial Group. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology, 2008, 134(1), 29-38.
97. Benamouzig, R.; Deyra, J.; Martin, A.; Girard, B.; Jullian, E.; Piednoir, B.; Couturier, D.; Coste, T.; Little, J.; Chaussade, S. The Association Pour La Prevention Par L'Aspirine Du Cancer Colorectal Study Group. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology, 2003, 125(2), 328-36.
98. Cole, B.F.; Logan, R.F.; Halabi, S.; Benamouzig, R.; Sandler, R.S.; Grainge, M.J.; Chaussade, S.; Baron, J.A. Aspirin for the chemoprevention of colorectal adenomas: meta-analysis of the randomized trials. J. Natl. Cancer Inst., 2009, 101(4),256-66.
99. Hirota, C.; Iida, M.; Aoyagi, K.; Matsumoto, T.; Tada, S.; Yao, T.; Fujishima, M. Effect of indomethacin suppositories on rectal poly - posis in patients with familial adenomatous polyposis. Cancer. 1996, 78(8),1660-5.
100. Phillips, R.K.; Wallace, M.H.; Lynch, P.M.; Hawk, E.; Gordon, G.B.; Saunders, B.P.; Wakabayashi, N.; Shen, Y.; Zimmerman, S.; Godio, L.; Rodrigues-Bigas, M.; Su, L-K.; Sherman, J.; Kelloff, G.; Levin, B.; Steinbach, G. the FAP Study Group. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial ade-nomatous polyposis. Gut, 2002, 50(6), 857-60.
101. Higuchi, T.; Iwama, T.; Yoshinaga, K.; Toyooka, M.; Taketo, M.M.; Sugihara, K. A randomized, double-blind, placebo-controlled trial of the effects of rofecoxib, a selective cyclooxy-genase-2 inhibitor, on rectal polyps in familial adenomatous polyposis patients. Clin. Cancer Res., 2003, 9(13),4756-60.
102. Burn, J.; Bishop, D.T; Chapman, P.D.; Elliott, F.; Bertario, L; Dunlop, M.G.; Eccles, D.; Ellis, A.; Evans, D.G.; Fodde, R.; Maher, E.R.; Moslein, G.; Vasen, H.F.A.; Coaker, J.; Phillips, R.K.S.; Bulow, S.; Mathers, J.C. the International CAPP Consortium. A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adeno-matous Polyposis. Cancer Prev. Res. (Phila)., 2011, 4(5), 655-665.
103. Burn, J.; Bishop, D.T.; Mecklin, J.P.; Macrae, F.; Möslein, G.; Olschwang, S.; Bisgaard, M-L.; Ramesar, R.; Eccles, D.; Maher, E.R.; Bertario, L.; Jarvinen, H.J.; Lindblom, A.; Evans, D.G.; Lubinski, J.; Morrison, P.J.; Ho, J.; Vasen, H.F.A.; Side, L.; Thomas, H.J.W.; Scott, R.J.; Dunlop, M.; Barker, G.; Elliott, F.; Jass, J.R.; Fodde, R.; Lynch, H.; Mathers, J.C. the CAPP2 Investigators. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N. Engl. J. Med., 2008, 359(24), 2567-78.
104. Chan, A.T.; Ogino, S.; Fuchs, C.S. Aspirin use and survival after diagnosis of colorectal cancer. JAMA, 2009, 302(6), 649-58.
105. Zell, J.A.; Ziogas, A.; Bernstein, L.; Clarke, C.A.; Deapen, D.; Largent, J.A.; Neuhausen, S.L.; Stram, D.O.; Ursin, G.; Anton-Culver H. Nonsteroidal anti-inflammatory drugs: effects on mortality after colorectal cancer diagnosis. Cancer, 2009, 115(24), 5662-71.
106. Zell, J.A.; Ziogas, A.; Bernstein, L.; Clarke, C.A.; Deapen, D.; Largent, J.A.; Neuhausen, S.L.; Stram, D.O.; Ursin, G.; Anton-Culver H. Meat consumption, nonsteroidal anti-inflammatory drug use, and mortality among colorectal cancer patients in the California Teachers Study. Cancer Prev. Res. (Phila)., 2010, 3(7), 865-75.
107. Sandler, R.S.; Halabi, S.; Baron, J.A.; Budinger, S.; Paskett., E.; Keresztes, R.; Petrelli, N.; Pipas, J.M.; Karp, D.D.; Loprinzi, C.L.; Steinbach, G.; Schilsky, R. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med., 2003, 348(10), 883-90.
108. *. J Gastroenterol. Hepatol., 2011, 26(3), 426-31.
109. Awtry, E.H.; Loscalzo, J. Aspirin. Circulation, 2000, 101(10),1206-18.
110. Roderick, P.J.; Wilkes, H.C.; Meade, T.W. The gastrointestinal toxicity of aspirin: an overview of randomised controlled trials. Br. J. Clin. Pharmacol., 1993, 35(3), 219-26.
111. Wallentin L.C. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: long-term effects on the risk for myocar-dial infarction, occurrence of severe angina and the need for revas-cularization. Research Group on Instability in Coronary Artery Disease in Southeast Sweden. J. Am. Coll. Cardiol., 1991, 18(7),1587-93.
112. He, J.; Whelton, P.K.; Vu, B.; Klag, M.J. Aspirin and risk of hemorrhagic stroke: a meta-analysis of randomized controlled trials. JAMA, 1998, 280(22),1930-5.
113. Lee T.H. Mechanism of aspirin sensitivity. Am. Rev. Respir. Dis., 1992, 145(2 Pt 2), S34-6.
114. U.S. Preventive Services Task Force. Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann. Intern. Med., 2007, 146(5), 361-4.
115. Ladabaum, U.; Chopra, C.L.; Huang, G.; Scheiman, J.M.; Chernew, M.E.; Fendrick, A.M. Aspirin as an adjunct to screening for prevention of sporadic colorectal cancer. A cost-effectiveness analysis. Ann. Intern. Med., 2001, 135(9),769-81.
116. Suleiman, S.; Rex, D.K.; Sonnenberg, A. Chemoprevention of colorectal cancer by aspirin: a cost-effectiveness analysis. Gastro-enterology, 2002, 122(1),78-84.
117. Cooper, K.; Squires, H.; Carroll, C.; Papaioannou, D.; Booth, A.; Logan, R.F.; Maguire, C.; Hind, D.; Tappenden, P. Chemoprevention of colorectal cancer: systematic review and economic evaluation. Health Technol. Assess., 2010, 14(32),1-206.
118. DuPont, A.W.; Arguedas, M.R.; Wilcox, C.M. Aspirin chemopre-vention in patients with increased risk for colorectal cancer: a cost-effectiveness analysis. Aliment. Pharmacol. Ther., 2007, 26(3), 431-41.
119. Slatore, C.G.; Au, D.H.; Littman, A.J.; Satia, J.A.; White, E. Association of Nonsteroidal Anti-Inflammatory Drugs with Lung Cancer: Results from a Large Cohort Study. Cancer Epidemiol. Biomarkers Prev., 2009, 18(4), 1203.
120. Tian, W.; Zhao, Y.; Liu, S.; Li, X. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur. J. Cancer Prev., 2010, 19(4), 288-98.
121. Bosetti, C.; Bravi., F.; Talamini, R; Montella, M; Negri, E.; La Vecchia, C. Aspirin and risk of endometrial cancer: a case-control study from Italy. Eur. J. Cancer Prev., 2010, 19(5), 401-3.
122. Bonifazi, M.; Gallus, S.; Bosetti, C.; Polesel, J.; Serraino, D.; Talamini, R.; Negri, E.; La Vecchia, C. Aspirin use and pancreatic cancer risk. Eur. J. Cancer Prev., 2010, 19(5), 352-4.
123. Nguyen, D.M.; Richardson, P.; El-Serag, H.B. Medications (NSAIDs, statins, proton pump inhibitors) and the risk of esophageal adenocarcinoma in patients with Barrett's esophagus. Gastroenterology, 2010, 138(7), 2260-6.
124. Rothwell, P.M.; Fowkes, F.G.; Belch, J.F.; Ogawa, H.; Warlow, C.P.; Meade, T.W. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet, 2011, 377(9759), 31-41.
125. Brenner, H.; Tao, S.; Haug, U. Low-dose aspirin use and performance of immunochemical fecal occult blood tests. JAMA, 2010, 304(22), 2513-20.
126. Rigas, B; Kashfi, K. Nitric-oxide-donating NSAIDs as agents for cancer prevention. Trends Mol. Med., 2004, 10(7), 324-30.
127. McIlhatton, M.A.; Tyler, J.; Burkholder, S.; Ruschoff, J.; Rigas, B.; Kopelovich, L.; Fishel, R. Nitric oxide-donating aspirin derivatives suppress microsatellite instability in mismatch repair-deficient and hereditary nonpolyposis colorectal cancer cells. Cancer Res., 2007, 67(22), 10966-75.
128. McIlhatton, M.A.; Tyler, J.; Kerepesi, L.A.; Bocker Edmonston, T.; Kucherlapati, M.H.; Edelmann, W., Kucherlapati, R.S.; Kopelovich, L.; Fishel, R. Aspirin and Low Dose Nitric Oxide-Donating Aspirin Increase Life Span in a Lynch Syndrome Mouse Model. Cancer Prev. Res., 2011, 4, 684-693